Drug interaction between amprenavir and lopinavir/ritonavir in salvage therapy [1]

AIDS

Volumn 16, Issue 5, 2002, Pages 797-798

  Khanlou, Homayoun ^a   Graham, Edwin ^a   Brill, Mari ^b   Farthing, Charles ^a  

^a AIDS HEALTHCARE FOUNDATION   (United States)

^b VERTEX PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; ANTIRETROVIRUS AGENT; LOPINAVIR; RITONAVIR;

CLINICAL ARTICLE; DRUG BLOOD LEVEL; HEMODIALYSIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; PRIORITY JOURNAL; VIRUS INFECTION; VIRUS RESISTANCE;

CARBAMATES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; PYRIMIDINONES; RITONAVIR; SALVAGE THERAPY; SULFONAMIDES;

EID: 0037192560     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200203290-00018     Document Type: Letter

References (6)

1. Dual boosted protease inhibitor regimens: Preliminary results in rescue therapy
2. Effect of reduced dose amprenavir in combination with lopinavir on plasma levels of amprenavir in patients infected with HIV
3. Minimal pharmacokinetic interaction between amprenavir and lopinavir
4. Inhibitory quotient and efficacy of amprenavir-lopinavir containing HAART in heavily pretreated HIV infected patients
5. Amprenavir plasma concentrations are dramatically decreased by association with ABT378/r in HIV-infected patients
6. Drug resistance and predicted virologic responses to human immunodeficiency virus type 1 protease inhibitor therapy